Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

• Status: Terminated
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis.

The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Treatments: Acitretin; Nicotinic Acids; Tazarotene

Criteria

Inclusion Criteria:

• Must give written informed consent

• Must be at least 18 years old

• Must have been diagnosed with stable plaque type psoriasis covering between 1 and 5% BSA

• NPF-PS ≥8 (based additive scores averaged over all lesions for erythema, scale, and thickness range of score = 0-5)

• No systemic or phototherapy in the 4 wks prior to entering the study

• No topical therapy other than emollients (no corticosteroids, vitamin D analogs, vitamin A analogs) in the 2 wks prior to entering the study

• Women on tazarotene gel must not be pregnant nor planning to become pregnant during the study and must be on two forms of birth control

• Subjects known to not tolerate oral acitretin at 25 mg/day and women of child-bearing potential may be enrolled and treated with topical tazarotene gel 0.1%

Exclusion Criteria:

Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of enrollment:

• Unstable disease

• Only treatable sites are in intertriginous areas or on face

• Subjects unable to tolerate frequency of visits

• NPF-PS severity score <8 additive score of erythema, scale, and thickness, averaged over all lesions

• History of inability to tolerate topical tazarotene 0.1% gel and or acitretin 25 mg/day

• Women of childbearing potential are excluded from the actretin arm of the study.